How Ibrutinib Has Transformed the Treatment Paradigm of CLL
September 21st 2017Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses how ibrutinib has transformed the treatment landscape of chronic lymphocytic leukemia.
The Potential of Ibrutinib Combinations for the Treatment of CLL
June 16th 2017Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.